Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.76 |
| ▸ | HINT1 | P49773 | 4/20 | 0.68 |
| ▸ | NT5E | P21589 | 2/20 | 0.68 |
| ▸ | PNP | P00491 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | GSK3A | P49840 | 2/20 | 0.64 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.64 |
| ▸ | TGM2 | P21980 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.62 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Guanosine SCHEMBL10811044 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL5550180 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL278157 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL12959061 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049416 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL7062800 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049608 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049417 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL24049467 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 | |
| Guanosine SCHEMBL20750695 | 1.00 | HPGD (0.76) | HPGDHINT1NT5EPNPPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| US-8664195-B2 | Phosphorus-containing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2014-03-04 | — | — | US | claimed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-7148349-B2 | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs | METABASIS THERAPEUTICS, INC. (US) | 2006-12-12 | — | — | US | claimed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | claimed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | disclosed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | CHIMERIX, INC. | 2018-08-02 | — | — | US | disclosed |
| US-9956239-B2 | Methods of treating retroviral infections and related dosage regimes | CHIMERIX, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170281658-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE | 2017-10-05 | — | — | US | disclosed |
| US-9765100-B2 | Nucleoside phosphonate salts | CHIMERIX, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| EP-3216789-A1 | METHODS OF TREATING VIRAL INFECTION | Chimerix, Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | METABASIS THERAPEUTICS, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1165570-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | Metabasis Therapeutics, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6312662-B1 | CONVERSION BY HUMAN LIVER MICROSOMES TO MPO3H2 | METABASIS THERAPEUTICS, INC. | 2001-11-06 | — | — | US | disclosed |
| WO-2000052015-A2 | NOVEL PHOSPHORUS-CONTAINING PRODRUGS | METABASIS THERAPEUTICS, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| US-6087489-A | INHIBITION OF GENE EXPRESSION; ANTICARCINOGENIC AGENTS; ANTITUMOR/ANTIPROLIFERATIVE AGENTS; DIAGNOSIS OF THYMIDYLATE SYNTHASE-ASSOCIATED RESPONSIVENESS TO ANTIFOLATE DRUGS | ISIS PHARMACEUTICALS INC. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0942916-A2 | NUCLEOSIDES | Medivir Aktiebolag (SE) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998021223-A1 | NUCLEOSIDES | MEDIVIR AB (SE) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180214464-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | HPGD 1841/4885HINT1 2117/4885NT5E 1344/4885 |
| US-20170281658-A1 | METHODS OF TREATING RETROVIRAL INFECTIONS AND RELATED DOSAGE REGIMES | TPMT, HAVCR2, REV1 | HPGD 1841/4885HINT1 2117/4885NT5E 1344/4885 |
| US-20020052345-A1 | Novel prodrugs for phosphorus-containing compounds | CCRL2, CCR4, ALK | HPGD 3661/4885HINT1 2929/4885NT5E 1529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.